Celladon's Advanced Heart Failure Treatment Fails In Mid-Stage Study
April 27, 2015 at 11:53 AM EDT
Shares of Celladon are down 70% after announcing that Mydicar failed to produce significant results in advanced heart-failure patients.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.